KYMR
Kymera Therapeutics, Inc. · Healthcare · Biotechnology
Input momentum (manajer yang sebanding): keluasan pemegang 0.0% · aliran saham -3.2% · posisi baru bersih -5.9% · formula
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q3 2025
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 3.10K | $81,538 | +1 | −1 |
| Q2 2026 | 101 | +13 | 52.72M | $6.01B | +15 | −2 |
| Q1 2026 | 91 | -4 | 48.20M | $4.01B | +6 | −11 |
| Q4 2025 | 94 | 0 | 48.74M | $3.79B | +1 | n/a |
| Q3 2025 | 17 | 0 | 32.08M | $1.82B | n/a | −1 |
| Q2 2025 | 15 | +3 | 31.72M | $1.38B | +3 | n/a |
| Q1 2025 | 9 | -3 | 16.51M | $451.78M | n/a | −3 |
| Q4 2024 | 12 | +1 | 15.63M | $628.72M | +1 | n/a |
| Q3 2024 | 10 | 0 | 13.10M | $619.83M | +1 | −1 |
| Q2 2024 | 10 | n/a | 13.21M | $394.27M | n/a | n/a |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 5.88M | +8.2% | $332.79M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | The Vanguard Group ✦ (pasif) | 5.42M | -3.5% | $306.87M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Wellington Management ✦ | 5.20M | -3.3% | $294.08M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 4 | T. Rowe Price ✦ | 5.10M | -25.7% | $288.51M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | BlackRock ✦ (pasif) | 4.37M | +5.2% | $247.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 6 | State Street Global Advisors ✦ (pasif) | 2.02M | +29.9% | $114.30M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (pasif) | 1.28M | +7.0% | $72.28M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Goldman Sachs Group ✦ | 711.44K | n/a | $40.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 429.98K | +170.2% | $24.34M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 385.40K | n/a | $21.81M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Morgan Stanley ✦ | 377.80K | n/a | $21.38M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 12 | Marshall Wace ✦ | 359.08K | +33.3% | $20.32M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 238.00K | -21.8% | $13.47M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 173.90K | -5.7% | $9.84M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Millennium Management ✦ | 94.96K | +68.0% | $5.37M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 41.82K | -91.9% | $2.37M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 8.62K | +6.6% | $487,892 | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
"Their weight" = porsi posisi dari nilai ekuitas 13F yang dilaporkan manajer tersebut: ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Norges Bank | $1.81M | adalah 0.0% |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 254 pemegang, 96.17M saham, $7.04B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang sekuritas ini yang dilacak: jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Officer, Director · 262 lbr · $30,423
Officer, Director · 4.88K lbr · $552,158
Officer, Director · 7.60K lbr · $869,782
Officer, Director · 8.23K lbr · $949,742
Officer, Director · 3.52K lbr · $392,826
Officer, Director · 5.51K lbr · $618,985
Officer · 3.02K lbr · $353,350
Officer · 2.14K lbr · $251,247
Officer · 1.21K lbr · $139,700
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi
3.3% dari kelas · Lihat pengajuan SEC asli ↗